[{"Assets_0_Q3_USD":640530000.0,"CommonStockSharesConverted_0_Q3_shares":117359502.0,"CommonStockSharesOutstanding_0_Q3_shares":117359502.0,"EarningsPerShareBasic_1_Q3_USD":-0.51,"EarningsPerShareBasic_3_Q3_USD":-1.86,"NetCashProvidedByUsedInOperatingActivitiesConverted_3_Q3_USD":-177384000.0,"StockholdersEquity_0_Q3_USD":459758000.0,"StockholdersEquityConverted_0_Q3_USD":521697000.0,"NetIncomeLossConverted_1_Q3_USD":-59980000.0,"NetIncomeLossConverted_3_Q3_USD":-187129000.0,"RevenuesConverted_1_Q3_USD":26741000.0,"RevenuesConverted_3_Q3_USD":26741000.0,"Ticker":"BBIO","CIK":"1743881","name":"BRIDGEBIO PHARMA, INC.","OfficialName":"BridgeBio Pharma Inc. Common Stock","form":"10-Q","period":"20190930","fy":"2019.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1594164456.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20191108"}]